Fecal MMP-9: A new noninvasive differential diagnostic and activity marker in ulcerative colitis

Inflammatory Bowel Diseases

Volumn 19, Issue 2, 2013, Pages 316-320

  Annaházi, Anita ^a,b   Molnár, Tamás ^a   Farkas, Klaudia ^a   Rosztóczy, András ^a   Izbéki, Ferenc ^a   Gecse, Krisztina ^a   Inczefi, Orsolya ^a   Nagy, Ferenc ^a   Földesi, Imre ^a   Szucs, Mónika ^a   Dabek, Marta ^b   Ferrier, Laurent ^b   Theodorou, Vassilia ^b   Bueno, Lionel ^b   Wittmann, Tibor ^a   Róka, Richárd ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b TOXALIM RESEARCH CENTRE IN FOOD TOXICOLOGY   (France)

Author keywords

Calprotectin; Disease activity score; MMP 9; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; GELATINASE B; HEMOGLOBIN; IRON;

ADULT; ARTICLE; COLONOSCOPY; CONTROLLED STUDY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FECES LEVEL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYDROGEN BREATH TEST; IRON BLOOD LEVEL; LEUKOCYTE COUNT; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PATIENT SELECTION; PRIORITY JOURNAL; REMISSION; THROMBOCYTE COUNT; ULCERATIVE COLITIS;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; COLONOSCOPY; DIAGNOSIS, DIFFERENTIAL; DIARRHEA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84876415302     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22996     Document Type: Article

References (27)

1. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426-431.
2. Saverymuttu SH, Hodgson HJ, Chadwick VS, et al. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut. 1986;27: 809-813.
3. Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol. 2002;14: 409-412.
4. Shine B, Berghouse L, Jones JE, et al. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta. 1985;148:105-109.
5. Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008;14: 32-39.
6. Kucharzik T, Maaser C, Lugering A, et al. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis. 2006; 12:1068-1083.
7. Kucharzik T, Walsh SV, Chen J, et al. Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am J Pathol. 2001;159: 2001-2009.
8. Saverymuttu SH, Chadwick VS, Hodgson HJ. Granulocyte migration in ulcerative colitis. Eur J Clin Invest. 1985;15:60-63.
9. Dabek M, Ferrier L, Roka R, et al. Luminal cathepsin g and proteaseactivated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis. Am J Pathol. 2009; 175:207-214.
10. Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992;27:793-798.
11. Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;58:176-180.
12. Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35: 642-647.
13. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000;47:506-513.
14. Baugh MD, Perry MJ, Hollander AP, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology. 1999;117:814-822.
15. Manfredi MA, Zurakowski D, Rufo PA, et al. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14:1091-1096.
16. Opdenakker G, Van den Steen PE, Van Damme J, Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 2001;22:571- 579.
17. Castaneda FE, Walia B, Vijay-Kumar M, et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology. 2005;129:1991-2008.
18. Nakajima M, Welch DR, Wynn DM, et al. Serum and plasma M(r) 92, 000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res. 1993;53:5802-5807.
19. Chan LW, Moses MA, Goley E, et al. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol. 2004;22: 499-506.
20. Fernandez CA, Yan L, Louis G, et al. The matrix metalloproteinase-9/ neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res. 2005;11:5390-5395.
21. Moses MA, Wiederschain D, Loughlin KR, et al. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998; 58:1395-1399.
22. Smith ER, Zurakowski D, Saad A, et al. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res. 2008; 14:2378-2386.
23. Lakatos G, Sipos F, Miheller P, et al. The behavior of matrix metalloproteinase-9 in lymphocytic colitis, collagenous colitis and ulcerative colitis. Pathol Oncol Res. 2012;18:85-91.
24. Kossakowska AE, Medlicott SA, Edwards DR, et al. Elevated plasma gelatinase A (MMP-2) activity is associated with quiescent Crohn's Disease. Ann N Y Acad Sci. 1999;30;878:578-580.
25. Gaya DR, Lyon TD, Duncan A, et al. Faecal calprotectin in the assessment of Crohn's disease activity. QJM. 2005;98:435-441.
26. Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2008;6:1218-1224.
27. Poullis A, Foster R, Mendall MA, et al. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol. 2003;18:756-762.